A telomere-related gene panel predicts the prognosis and Immune Status in gastric cancer
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Telomeres play a crucial role in the development and progression of cancers. However, the impact of telomere-related genes (TRGs) on the prognosis and tumor immune microenvironment (TIME) of gastric cancer (GC) remains unclear. Therefore, a comprehensive investigation of the association between TRGs and GC is necessary. The TRG risk panel was constructed by combining differentially expressed gene analysis, weighted gene co-expression network analyses, the Least Absolute Shrinkage and Selection Operator regression, and stepwise regression analysis in the TCGA cohort and has been validated in a GEO cohort. The major impacts of the signature on the TIME and immunotherapy response were also evaluated. The prognosis model comprised 9 TRGs (CABP2, CALML6, CFAP58, DST, ELOVL2, HIST1H3G, MYF6, PDE1B and TOP3B), stratifying patients into two risk groups. Individuals with low-risk scores exhibited superior prognoses than those with high-risk scores ( P < 0.001). The prognostic signature was found to be an independent factor with good predictive power for overall survival. The high-risk group tended to have higher TME scores and an inert immune status with a higher infiltration proportion of Treg cells, M2 macrophages, resting dendritic cells and resting NK cells. Additionally, the low-risk group had higher TMB, lower TIDE and a higher immunotherapy response rate. Additionally, we confirmed the expression of the nine genes in GC tissues using RT-qPCR. Our TRG-based panel has a significant role in the prognosis, TIME, and immunotherapy response. This may suggest that the TRG panel could be a powerful tool for guiding clinical treatment decisions.